Komorowski et al., [64] evaluated the blood concentrations of angiogenic growth factors (VEGF and FGF), matrix metalloproteinases and tissue inhibitors of matrix in 22 patients with thyroid cancers (three of them with MTC). This evidence concerns the gene VEGFA and thyroid gland carcinoma.